Filana Therapeutics Inc (NASDAQ: FLNA) is a clinical-stage biopharmaceutical company developing drug candidates for neurological disorders. The company has no approved products and has generated no revenue from product sales as of the fiscal year ended December 31, 2025, reporting an accumulated deficit of $496.1 million at that date. Its lead product candidate, simufilam, was previously in Phase 3 development for mild-to-moderate Alzheimer's disease across two trials enrolling 1,900 patients between 2021 and 2025. Both trials, RETHINK-ALZ and REFOCUS-ALZ, failed to meet their pre-specified efficacy endpoints, and the Alzheimer's disease program was phased out by the second quarter of 2025. Filana has since redirected simufilam toward tuberous sclerosis complex (TSC)-related epilepsy, though the FDA placed a full clinical hold on planned clinical studies as of the filing date. Day-to-day operations are based in Austin, Texas. The company funds operations through capital raises rather than product revenue.

Revenue model

No product revenue as of December 31, 2025. Operations are funded through capital markets. The company disclosed an accumulated deficit of $496.1 million at December 31, 2025, with losses driven by research and development costs, personnel expenses, and general corporate expenses.

Products and services

Simufilam is the lead product candidate, an oral small molecule previously studied at 100 mg and 50 mg doses twice daily in Phase 3 Alzheimer's disease trials (RETHINK-ALZ and REFOCUS-ALZ). Both Phase 3 trials failed to meet efficacy endpoints, and the Alzheimer's program was discontinued by Q2 2025. As of the 10-K filed 2026-03-12, simufilam is being evaluated for TSC-related epilepsy, with a full FDA clinical hold in place delaying trial initiation beyond the first half of 2026.

Customers and end markets

No commercial customers as of December 31, 2025. Target end markets are patients with neurological disorders, specifically TSC-related epilepsy as the current development focus. Commercial success, if any future product is approved, would depend on third-party payor coverage and reimbursement at federal, state, and private levels.

Value-chain role

Drug developer with no internal manufacturing. Relies on third-party contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), clinical investigational sites, and non-clinical research labs for development and supply of product candidates.

Geographic exposure

Principal offices located in Austin, Texas. Regulatory interactions primarily with the U.S. FDA.

Source: SEC 10-K, filed 2026-03-12

Industry: Pharmaceutical Preparations Peers: Amylyx Pharmaceuticals Inc Arvinas Inc Axsome Therapeutics Inc Pacira Biosciences Inc Johnson & Johnson Revance Therapeutics, Inc. Supernus Pharmaceuticals Inc Ventyx Biosciences, Inc.